Integra LifeSciences Holdings Corporation (IART) financial statements and ratios from SEC XBRL: revenue $1.64B (TTM), net margin -31.6%, revenue growth 1.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $1.64B |
| Net Margin | -31.6% |
| Revenue Growth (YoY) | 1.5% |
| EPS Growth (YoY) | 7388.9% |
| FCF Growth (YoY) | -224.4% |
| EV / EBITDA | 33.0 |
| Price / Book | 1.24 |
| Price / Sales | 0.80 |
| FCF Yield | -2.3% |
| DCF Value (model) | $4.33 |
| DCF Upside vs Price | -73.9% |
| Altman Z-Score | 0.70 (distress) |
| Piotroski F-Score | 4/9 |
| Sector P/E (Healthcare) | 21.6 |
IART overview · IART earnings · IART KPIs · IART investor relations · IART ownership · IART peers · IART filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.